AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03250286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography (ERCP) is performed with duodenoscope (Olympus JF-260V or TJF-260V) by four endoscopists.~* In the EUS-ERCP group, ERCP is used to remove bile duct stones diagnosed via EUS. Therefore, only ERCP is performed in patients with choledocholithiasis in EUS.~* In the ERCP group, diagnosis and treatment of bile duct stones are performed with ERCP.
Study NCT03250286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography (ERCP) is performed with duodenoscope (Olympus JF-260V or TJF-260V) by four endoscopists.~* In the EUS-ERCP group, ERCP is used to remove bile duct stones diagnosed via EUS. Therefore, only ERCP is performed in patients with choledocholithiasis in EUS.~* In the ERCP group, diagnosis and treatment of bile duct stones are performed with ERCP.
Study NCT03579095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cereboost
Description: 200mg Cereboost and Maltodextrin capsules
Study NCT03579095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg Maltodextrin capsules
Study NCT01826409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Red Ginseng
Description: Fermented red ginseng 2.7g/day for 4 weeks
Study NCT01826409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2.7g/day for 4 weeks
Study NCT01415557 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Fortified Control Product
Description: Non-Fortified Control Beverage
Study NCT01415557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient Fortified Test Product
Description: Micronutrient Fortified Test Beverage
Study NCT00737490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sequential Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)
Description: Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm~Using one of the FDA approved St. Jude devices, depending on MD preference.
Study NCT00737490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)
Description: simultaneous BiV pacing.~Using one of the FDA approved St. Jude devices, depending on MD preference.
Study NCT03393728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propanolol
Description: 72-hour propanolol before specific treatment of hyperthyroidism
Study NCT02459951 — intervention group
Intervention type: OTHER
Intervention: clenched fist
Description: Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.
Study NCT00667095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Instillation
Description: Botox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.
Study NCT00667095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMSO Instillation
Description: DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
Study NCT00667095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DMSO Instillation
Description: DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
Study NCT02608788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S.L.®
Description: 1.5mg/ml Benzydamine hydrochloride, S.L.® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Study NCT02608788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difflam Forte ®
Description: 3.0mg/ml Benzydamine hydrochloride ,  Difflam Forte ® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Study NCT02566005 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley bulb
Description: a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours.
Study NCT01231165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: 5mg/daily for 12th months
Study NCT01231165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrates, clopidogrel, aspirin, statins
Description: Comparative Efficacious Research
Study NCT02562625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Powder solution for infusion
Study NCT02562625 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 24Gy
Study NCT03276741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: gastric soft/bland diet
Description: Patients in the experimental group will have a gastric soft/bland diet available.
Study NCT00317044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole 40 mg twice daily
Study NCT00317044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole 40 mg once daily
Study NCT00317044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study NCT04647110 — intervention group
Intervention type: DRUG
Intervention: crizotinib
Description: as provided in real world practice
Study NCT04647110 — intervention group
Intervention type: DRUG
Intervention: alectinib
Description: as provided in real world practice
Study NCT04647110 — intervention group
Intervention type: DRUG
Intervention: brigatinib
Description: as provided in real world practice
Study NCT04647110 — intervention group
Intervention type: DRUG
Intervention: ceritinib
Description: as provided in real world practice
Study NCT04647110 — intervention group
Intervention type: DRUG
Intervention: lorlatinib
Description: as provided in real world practice
Study NCT01067820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks
Study NCT01067820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo RVX000222
Description: capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks
Study NCT00975091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
Study NCT00975091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
Study NCT00755820 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exposure Therapy + D-Cycloserine
Description: Exposure therapy with d-cycloserine medication
Study NCT00755820 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exposure Therapy + Placebo
Description: Exposure therapy with placebo medication
Study NCT00755820 — intervention group
Intervention type: BEHAVIORAL
Intervention: Supportive Psychotherapy
Description: Supportive psychotherapy
Study NCT02285829 — intervention group
Intervention type: DRUG
Intervention: Rocuronium Bromide, Cisatracurium Besylate
Description: Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation. Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012 mg/kg/min IV. Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min. Following recovery and baseline screw stimulation at TOF >0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached. Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
Study NCT02285400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP level
Description: CPAP level ranges between 4 and 12 cm water column (cmH2O), each pressure increment for 1 cmH2O.
Study NCT02104063 — intervention group
Intervention type: PROCEDURE
Intervention: MRI-PET
Description: Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
Study NCT04807361 — intervention group
Intervention type: BEHAVIORAL
Intervention: Auditory biofeedback traing
Description: Subjects who wear MFCLs for myopia control will receive one episode of auditory biofeedback training, and their accommodative responses to various demands (0, 2.5, 3, and 4 D) before and after the training were measured using a power refractor.
Study NCT00318292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine and epinephrine
Description: 20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
Study NCT00318292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 ml normal saline injection.
Study NCT02633449 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cognitive behavioral therapy
Description: 12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks
Study NCT02633449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy
Description: 12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks
Study NCT02633449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: 12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks
Study NCT02633449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, 1-2 mA, anode over electrode position F3, cathode over F4
Study NCT02633449 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham-tDCS
Description: sham transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, anode over electrode position F3, cathode over F4
Study NCT00522392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00522392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bortezomib
Description: Given IV
Study NCT00522392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO
Study NCT00522392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO
Study NCT00522392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given PO
Study NCT02109081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02109081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01485978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.
Study NCT01485978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to ramipril
Description: Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.
Study NCT01485978 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril
Description: Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.
Study NCT04268134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplement
Description: 4 capsules taken by mouth each day for 24 weeks (starting at the week 12 visit).
Study NCT05057390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New Human Milk Fortifier (NHMF)
Description: The case study product will be added to human milk during the hospitalization and will continue after discharge for at least 1 week (7 days), to obtain community data. NHMF prescription will be specified on an individual basis by the investigating Dietitian responsible for the infant's nutritional management. The intervention period will end when the infant does not require NHMF (according to local neonatal guidelines and/or clinical indication).~The case study product will be labelled specifically for the case study and will be available in a powder format.~Full preparation, storage and safety instructions will be given to the parent/caregiver by the investigating Dietitian before commencing the case study product to ensure its correct and safe use.
Study NCT02064764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter
Study NCT02064764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Front Advance™ Cardiac Cryoablation System
Study NCT02064764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arctic Front Advance™ Cardiac Cryoablation System
Study NCT02608788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acular®
Description: 5％ Ketorolac Tromethamine ,  Acular®  spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Study NCT02608788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Distilled water spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Study NCT03122990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FM-SRP
Description: Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
Study NCT03122990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Q-SRP
Description: Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented.Performed in 3 weeks time frame.
Study NCT03211182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification intervention
Description: healthy lifestyle education and individualized counseling by well-trained case manager. The main goals of the lifestyle intervention included regular moderate intensity physical activity 150 min per week or more, and dietary strategies which reduce the risk of developing diabetes. The dietary suggestion was modified by Dietary Approaches to Stop Hypertension (DASH) Diet. Participants with BMI>= 24 kg/m2 were encouraged to gradually lose weight at a rate of 0.5-1.0 kg per week until they achieved a BMI of 24 kg/m2.
Study NCT00542191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin
Description: DOXORUBICIN 24mg/m2 IV plus CYCLOPHOSPHAMIDE 60mg/m2 PO weekly x 12 successive weeks followed by PACLITAXEL 80mg/m2 IV over 1 hour plus CARBOPLATIN AUC 2 IV weekly x 12 successive weeks
Study NCT00542191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Definitive Surgery
Description: Standard of care definitive surgery as determined by medical provider
Study NCT00542191 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard of care RADIATION THERAPY as indicated
Study NCT02119715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF 100μg/kg
Description: Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
Study NCT02119715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF:150 μg/kg
Description: Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
Study NCT02119715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF 5 μg/kg/day
Description: Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.
Study NCT01015508 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Very Low Energy Diet (VLED)
Description: a VLED (Modifast) for 2 months in order to reduce body weight
Study NCT01015508 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Weight maintenance
Description: 10 months
Study NCT05202457 — intervention group
Intervention type: PROCEDURE
Intervention: Elective surgery
Description: Patient undergoing elective or urgent surgery
Study NCT03015103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intimate Lubrificant Gel
Description: All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
Study NCT03071029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly PAFP rates displayed at clinics.
Description: Providers will receive visual and text feedback on their centre's PAFP uptake rates as they compare to the uptake rates of other centres. The feedback will be delivered monthly in a physical paper format.
Study NCT01900964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTFE membrane
Description: The non-resorbable PTFE barrier membrane will be surgically placed in conjunction with a ridge preservation procedure.
Study NCT02620904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Study NCT02620904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03006627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: postoperative morphine
Description: Postoperatively, A loading dose of morphine will be given in incremental doses of 1 mg 5 min apart, till the VAS score reached ≤3. The dose of morphine required to reduce the VAS score to ≤3 will be recorded. Subsequently, PCA pump will be configured to deliver a bolus of 1 mg with a lock-out period lasting for 20 min.
Study NCT01582880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Used to treat donor cornea before implantation
Study NCT04381767 — intervention group
Intervention type: DEVICE
Intervention: EYE-SYNC
Description: Evaluation of oculomotor performance using visual presentation and eye tracking analysis
Study NCT03420560 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: warmer temperature
Description: Patients before general anesthesia induction will send to warmer operation Injection pain was accessed with (Visual analogous scale)VAS.
Study NCT03420560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: warmer temperature
Description: Patients before general anesthesia induction will send to warmer operation Injection pain was accessed with (Visual analogous scale)VAS.
Study NCT00079378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT00079378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid
Description: Given orally
Study NCT00079378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00079378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00956930 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 glass microspheres
Description: Patients undergo radioembolization.
Study NCT01615497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBT4CBT for alcohol plus TAU
Description: Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus TAU